A number of investment brokers have recently updated their price targets on shares of ARCA biopharma, Inc. (ABIO). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/23/2016 – ARCA biopharma, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 4 price target on the stock.

02/23/2016 – ARCA biopharma, Inc. had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 4 price target on the stock.

05/03/2015 – ARCA biopharma, Inc. had its “hold” rating reiterated by analysts at Zacks.

10/09/2013 – Dawson James began new coverage on ARCA biopharma, Inc. giving the company a “buy” rating. They now have a USD 3.75 price target on the stock.

The share price of ARCA biopharma, Inc. (ABIO) was down -4.10% during the last day of trading, with a day high of 3.85. 6137 shares were traded during the last session.

The stock’s 50 day moving average is 3.72 and its 200 day moving average is 4.31. The stock’s market capitalization is 33.85M. ARCA biopharma, Inc. has a 52-week low of 3.05 and a 52-week high of 10.85.

View other investors thoughts on ARCA biopharma, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.